Virtus LifeSci Biotech Clinical Trials ETF
19 hedge funds and large institutions have $15.7M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$781K | |
| 2 | +$523K | |
| 3 | +$52.3K | |
| 4 |
LPL Financial
San Diego,
California
|
+$26.6K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$16.6K |
Top Sellers
| 1 | -$4.56M | |
| 2 | -$604K | |
| 3 | -$488K | |
| 4 |
BRC
BHF RG Capital
Scottsdale,
Arizona
|
-$212K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$123K |